CVC  Lilly Ventures

     Office Locations:

115 W. Washington St, South Tower, Suite 1680
Indianapolis, IN 46204
Phone: 317-429-0140
Fax: 317-759-2819



  • Early
  • Expansion
  • Growth



  • Information Technology
  • Life Sciences & Healthcare
  • Medical Device



    Lilly Ventures is the venture capital arm of Eli Lilly and Company, a leading innovation-driven pharmaceutical company. The fund's primary goal is to facilitate the success of companies in Lilly's areas of focus through early to expansion stage investments and value-adding resources. Lilly Ventures currently has $200 million under management and focuses on three major areas of interest: Biotechnology, targeting investments in biotechnology companies that leverage proprietary drug discovery or development technologies to build a robust pipeline; Healthcare IT, targeting investments in start-up companies with innovative network technologies that promise to have a transformational impact on the current pharmaceutical business model; and Medical Technology, targeting investments in companies focusing on the convergence of pharmaceuticals, devices or diagnostics. The fund also has a sister fund, Lilly Asian Ventures, which was established in 2007, and has a geographic focus on the emerging life science businesses of east and south Asia, particularly China and India.

    Investment Firm Key

       VC = Venture Capital
       PE = Private Equity
       A = Angel
       I = Incubator
       MB = Merchant Bank
       VD = Venture Debt
       FI = Family Investment Office
       FOF = Fund of Funds
       ED = Economic Development Office   
       TT = Technology Transfer Office
       CVC = Corporate Venture Capital
       SEC = Secondary Purchaser
       HF = Hedge Fund/Mutual Fund
    Venture Capital
    Seed Stage
    (includes "pre-seed," or
    concept stage)
    No Revenue
    Early StageMinimal
    Growth Stage
    (also called Mid-stage)
    Expansion Stage
    (also called Late-stage)
    $7M and greater
    Private Equity
    Lower Middle Market$10M-$249M
    Middle Market$250M-$499M
    Upper Middle Market$500M-$1B
    Large Cap>$1B

    Investment Team:

    Name   Title
    Get the complete investment team + individual email addresses for investment team partners. Get personal images, LinkedIn links, investment specialties, office locations and more with a National Database subscription.
    Armen Shanafelt General Partner
    Lisa Belas Office Manager
    S. Edward Torres Co-Founder and Managing Director
    Steve Hall General Partner


    Recent Funding Events (trailing 12 months):







      Nimbus Therapeutics





    Portfolio companies include:

      Aeglea Biotherapeutics
        web link

      Aileron Therapeutics
        web link

      Avid Radiopharmaceuticals
        web link

        web link

      Cerulean Pharma
        web link

      CGI Pharmaceuticals
        web link

      Coherus Biosciences
        web link

      Cylene Pharmaceuticals
        web link

      Forma Therapeutics
        web link

        web link

        web link

      Hydra Biosciences
        web link

      InCube Ventures
        web link

        web link

      Innocrin Pharmaceuticals
        web link

        web link

      Kymera Therapeutics
        web link

      Lysosomal Therapeutics
        web link

      Nimbus Discovery
        web link

      Nimbus Therapeutics
        web link

        web link

      Protagonist Therapeutics
        web link

        web link

        web link

      Surface Oncology
        web link

      Sutro Biopharma
        web link

      Symic Biomedical
        web link

      Viamet Pharmaceuticals
        web link


    Recent News: